|
31 Companies |
|
25 Products |
|
25 Products |
|
26 Mechanisms of Action |
|
1 Trial |
|
222 News |
|
| 12345» |
- | Enrollment change, Trial completion date, Trial withdrawal, IO biomarker, Virus specific T cells: VISIT: Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - May 9, 2019
P1/2, N=0, Withdrawn, Sponsor: St. Anna Kinderkrebsforschung
N=30 --> 0 | Trial completion date: Mar 2020 --> Apr 2019 | Recruiting --> Withdrawn
- cretostimogene grenadenorepvec (CG0070) / Kissei, CG Oncology
Trial withdrawal, Oncolytic virus: exBOND: Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Feb 1, 2019
P2, N=0, Withdrawn, Sponsor: Cold Genesys, Inc.
N=30 --> 0 | Trial completion date: Mar 2020 --> Apr 2019 | Recruiting --> Withdrawn No Longer Available --> Withdrawn
- | Trial completion: Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (clinicaltrials.gov) - Jan 23, 2019
P1, N=36, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
No Longer Available --> Withdrawn Active, not recruiting --> Completed
- | INGN 225 / Lumos Pharma
Trial completion, Trial completion date: Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer (clinicaltrials.gov) - Dec 12, 2018
P1/2, N=24, Completed, Sponsor: University of Nebraska
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> Jan 2018
- | Enrollment closed, Trial completion date: Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (clinicaltrials.gov) - Dec 5, 2018
P1, N=36, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> Jan 2018 Completed --> Active, not recruiting | Trial completion date: Mar 2018 --> Jan 2019
- | VCN-01 / Theriva Bio
Trial completion, Enrollment change, Oncolytic virus, Metastases: A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane (clinicaltrials.gov) - Oct 1, 2018
P1, N=8, Completed, Sponsor: VCN Biosciences, S.L.
Completed --> Active, not recruiting | Trial completion date: Mar 2018 --> Jan 2019 Active, not recruiting --> Completed | N=18 --> 8
- | Trial completion date, Viral vector: Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer (clinicaltrials.gov) - Sep 11, 2018
P1, N=17, Completed, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Active, not recruiting --> Completed | N=18 --> 8 Trial completion date: Mar 2014 --> Sep 2018
- | Enrollment change, Trial withdrawal, Virus specific T cells: Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) (clinicaltrials.gov) - Jul 23, 2018
P1, N=0, Withdrawn, Sponsor: ViraCyte
Trial completion date: Mar 2014 --> Sep 2018 N=10 --> 0 | Recruiting --> Withdrawn
- | tasadenoturev (DNX-2401) / DNAtrix
Trial completion: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Jul 16, 2018
P1b, N=37, Completed, Sponsor: DNAtrix, Inc.
N=10 --> 0 | Recruiting --> Withdrawn Active, not recruiting --> Completed
- | VCN-01 / Theriva Bio
Trial completion date, Oncolytic virus, Metastases: A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane (clinicaltrials.gov) - May 3, 2018
P1, N=18, Active, not recruiting, Sponsor: VCN Biosciences, S.L.
Active, not recruiting --> Completed Trial completion date: Apr 2018 --> Sep 2018
- | Trial completion, Trial completion date: Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (clinicaltrials.gov) - Apr 12, 2018
P1, N=36, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Trial completion date: Apr 2018 --> Sep 2018 Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Mar 2018
- | GSK3390107 / GSK
Enrollment change: Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults (clinicaltrials.gov) - Apr 5, 2018
P1, N=143, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial completion date: Jan 2019 --> Mar 2018 N=50 --> 143
- | Zirgan (ganciclovir ophthalmic gel) / Bausch Health, Thea Laboratories
Trial completion, Enrollment change, Trial primary completion date: A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis (clinicaltrials.gov) - Feb 28, 2018
P4, N=20, Completed, Sponsor: Lifelong Vision Foundation
N=50 --> 143 Recruiting --> Completed | N=80 --> 20 | Trial primary completion date: Dec 2015 --> Dec 2014
- |||| RT-100 / Renova Therapeutics
Trial completion, Trial completion date: AC6 Gene Transfer for CHF (clinicaltrials.gov) - Feb 9, 2018
P1/2, N=56, Completed, Sponsor: Hammond, H. Kirk, M.D.
Recruiting --> Completed | N=80 --> 20 | Trial primary completion date: Dec 2015 --> Dec 2014 Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Nov 2017
- Enrollment change, Trial termination, Trial primary completion date: Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT (clinicaltrials.gov) - Feb 1, 2018
P=N/A, N=1, Terminated, Sponsor: Cell Medica Ltd
Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Nov 2017 N=120 --> 1 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Feb 2017; Lack of study recruitment
- tasadenoturev (DNX-2401) / DNAtrix
Trial primary completion date: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Jan 31, 2018
P1b, N=37, Active, not recruiting, Sponsor: DNAtrix, Inc.
N=120 --> 1 | Recruiting --> Terminated | Trial primary completion date: May 2018 --> Feb 2017; Lack of study recruitment Trial primary completion date: Aug 2017 --> Mar 2018
- | INGN 225 / Lumos Pharma
Trial primary completion date: Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer (clinicaltrials.gov) - Oct 26, 2017
P1/2, N=24, Active, not recruiting, Sponsor: University of Nebraska
Trial primary completion date: Aug 2017 --> Mar 2018 Trial primary completion date: Dec 2014 --> Dec 2018
- | tasadenoturev (DNX-2401) / DNAtrix
Trial completion, Oncolytic virus: D24GBM: Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (clinicaltrials.gov) - Oct 24, 2017
P1, N=31, Completed, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
Trial primary completion date: Dec 2014 --> Dec 2018 Active, not recruiting --> Completed
- |||| GSK3390107 / GSK
Trial completion: A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children (clinicaltrials.gov) - Oct 11, 2017
P2, N=600, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Mobilan (M-VM3) / Cytocom
Trial completion, Enrollment change, Trial primary completion date: Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer (clinicaltrials.gov) - Sep 20, 2017
P1, N=32, Completed, Sponsor: Panacela Labs LLC
Active, not recruiting --> Completed Recruiting --> Completed | N=44 --> 32 | Trial primary completion date: Mar 2017 --> Sep 2017
- | Trial completion: Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults (clinicaltrials.gov) - Sep 8, 2017
P1, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=44 --> 32 | Trial primary completion date: Mar 2017 --> Sep 2017 Active, not recruiting --> Completed
- | Trial primary completion date, Oncolytic virus, Metastases: Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma (clinicaltrials.gov) - Aug 29, 2017
P1, N=14, Completed, Sponsor: Institut Catal
Active, not recruiting --> Completed Trial primary completion date: Jun 2014 --> Dec 2016
- | Enrollment change: Study of the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine (clinicaltrials.gov) - Jul 2, 2017
P1, N=24, Terminated, Sponsor: McMaster University
Trial primary completion date: Jun 2014 --> Dec 2016 N=48 --> 24
- ||| Zabdeno (monovalent ebola virus vaccine) / J&J
Trial completion: A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants (clinicaltrials.gov) - Jun 14, 2017
P1, N=164, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
N=48 --> 24 Active, not recruiting --> Completed
- | Trial completion: Specific Respiratory Infections as Triggers of Acute Medical Events (clinicaltrials.gov) - May 4, 2017
P=N/A, N=787000, Completed, Sponsor: University College, London
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer (clinicaltrials.gov) - Apr 7, 2017
P1, N=10, Completed, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | GSK3390107 / GSK
Trial completion, Trial primary completion date: Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults (clinicaltrials.gov) - Apr 7, 2017
P1, N=50, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Apr 2017
- |||| GSK3390107 / GSK
Trial completion: A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults (clinicaltrials.gov) - Feb 27, 2017
P2, N=3024, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Apr 2017 Active, not recruiting --> Completed
- Virus specific T cells: Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A) (clinicaltrials.gov) - Feb 23, 2017
P1, N=10, Not yet recruiting, Sponsor: ViraCyte
Active, not recruiting --> Completed Initiation date: Jan 2016 --> Jun 2017 | Trial primary completion date: Dec 2017 --> Dec 2018
- ||| New trial: ADenoVirus Initiative Study in Epidemiology in Italy (clinicaltrials.gov) - Feb 16, 2017
P=N/A, N=241, Completed, Sponsor: NicOx
- ||||||| Zabdeno (monovalent ebola virus vaccine) / J&J
Trial completion: A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (clinicaltrials.gov) - Feb 8, 2017
P3, N=525, Completed, Sponsor: Janssen Vaccines & Prevention B.V.
Initiation date: Jan 2016 --> Jun 2017 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
- ||| Trial completion, Enrollment change, Trial initiation date: ADenoVirus Initiative Study in Epidemiology in Germany (clinicaltrials.gov) - Jan 11, 2017
P=N/A, N=240, Completed, Sponsor: NicOx
Active, not recruiting --> Completed Recruiting --> Completed | N=500 --> 240 | Initiation date: Oct 2013 --> Apr 2014
- ||| Trial completion, Enrollment change: ADenoVirus Initiative Study in Epidemiology in Spain (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=386, Completed, Sponsor: NicOx
Recruiting --> Completed | N=500 --> 240 | Initiation date: Oct 2013 --> Apr 2014 Recruiting --> Completed | N=500 --> 386
- GSK3390107 / GSK
Trial primary completion date: Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults (clinicaltrials.gov) - Jan 10, 2017
P1, N=50, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=500 --> 386 Trial primary completion date: Dec 2016 --> Dec 2017
- Tembexa (brincidofovir oral) / SymBio Pharma
Retrospective data, Trial termination: A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304 (clinicaltrials.gov) - Jan 9, 2017
P=N/A, N=100, Terminated, Sponsor: Chimerix
Trial primary completion date: Dec 2016 --> Dec 2017 Completed --> Terminated; Study was terminated early due to results from previous CMX study
- ||| Zabdeno (monovalent ebola virus vaccine) / J&J
Trial completion: A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants (clinicaltrials.gov) - Dec 8, 2016
P1, N=78, Completed, Sponsor: Crucell Holland BV
Completed --> Terminated; Study was terminated early due to results from previous CMX study Active, not recruiting --> Completed
- ||| Zabdeno (monovalent ebola virus vaccine) / J&J
Trial completion: A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants (clinicaltrials.gov) - Dec 8, 2016
P1, N=72, Completed, Sponsor: Crucell Holland BV
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New trial: Specific Respiratory Infections as Triggers of Acute Medical Events (clinicaltrials.gov) - Dec 6, 2016
P=N/A, N=770000, Active, not recruiting, Sponsor: University College, London
- tasadenoturev (DNX-2401) / DNAtrix
Enrollment closed: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Dec 6, 2016
P1b, N=37, Active, not recruiting, Sponsor: DNAtrix, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine (clinicaltrials.gov) - Nov 21, 2016
P1, N=22, Completed, Sponsor: International AIDS Vaccine Initiative
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Zabdeno (monovalent ebola virus vaccine) / J&J
Trial completion: A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (clinicaltrials.gov) - Nov 17, 2016
P3, N=329, Completed, Sponsor: Crucell Holland BV
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Tembexa (brincidofovir oral) / SymBio Pharma
Trial completion, Retrospective data, Enrollment change: A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304 (clinicaltrials.gov) - Nov 14, 2016
P=N/A, N=100, Completed, Sponsor: Chimerix
Active, not recruiting --> Completed Enrolling by invitation --> Completed | N=260 --> 100
- Enrollment closed: Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults (clinicaltrials.gov) - Oct 26, 2016
P1, N=36, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Enrolling by invitation --> Completed | N=260 --> 100 Recruiting --> Active, not recruiting
- Enrollment open, IO biomarker, Virus specific T cells: VISIT: Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Oct 19, 2016
P1/2, N=30, Recruiting, Sponsor: St. Anna Kinderkrebsforschung
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || Zabdeno (monovalent ebola virus vaccine) / J&J
Enrollment closed: A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants (clinicaltrials.gov) - Oct 3, 2016
P1, N=164, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Zabdeno (monovalent ebola virus vaccine) / J&J
Enrollment closed: A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (clinicaltrials.gov) - Sep 30, 2016
P3, N=525, Active, not recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- GSK3390107 / GSK
Trial primary completion date: Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults (clinicaltrials.gov) - Sep 6, 2016
P1, N=50, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Dec 2016
- |||| Trial completion: A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine (clinicaltrials.gov) - Sep 1, 2016
P2, N=500, Completed, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Trial primary completion date: Aug 2016 --> Dec 2016 Active, not recruiting --> Completed
- ||| Zabdeno (monovalent ebola virus vaccine) / J&J
Enrollment open: A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants (clinicaltrials.gov) - Aug 19, 2016
P1, N=164, Recruiting, Sponsor: Janssen Vaccines & Prevention B.V.
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- tasadenoturev (DNX-2401) / DNAtrix
Phase classification: TARGET-I: DNX-2401 With Interferon Gamma (IFN-?) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (clinicaltrials.gov) - Aug 2, 2016
P1b, N=36, Recruiting, Sponsor: DNAtrix, Inc.
Active, not recruiting --> Recruiting Phase classification: P1 --> P1b